These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31104135)

  • 41. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
    Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
    Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
    Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A
    Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
    Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Lachmann RH; Logan S
    J Inherit Metab Dis; 2014 Nov; 37(6):945-52. PubMed ID: 24906254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.
    Al-Hassnan Z; Hashmi NA; Makhseed N; Omran TB; Al Jasmi F; Teneiji AA
    Orphanet J Rare Dis; 2022 Oct; 17(1):388. PubMed ID: 36303251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.
    Wenninger S; Gutschmidt K; Wirner C; Einvag K; Montagnese F; Schoser B
    J Neurol; 2021 Aug; 268(8):2943-2950. PubMed ID: 33625582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The new horizons for treatment of Late-Onset Pompe Disease (LOPD).
    Guémy C; Laforêt P
    Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges in diagnosis and treatment of late-onset Pompe disease.
    Desnuelle C; Salviati L
    Curr Opin Neurol; 2011 Oct; 24(5):443-8. PubMed ID: 21892081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pompe disease gene therapy.
    Byrne BJ; Falk DJ; Pacak CA; Nayak S; Herzog RW; Elder ME; Collins SW; Conlon TJ; Clement N; Cleaver BD; Cloutier DA; Porvasnik SL; Islam S; Elmallah MK; Martin A; Smith BK; Fuller DD; Lawson LA; Mah CS
    Hum Mol Genet; 2011 Apr; 20(R1):R61-8. PubMed ID: 21518733
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnosis recommendations for late-onset Pompe disease].
    Brito-Avô L; Alves JD; Costa JM; Valverde A; Santos L; Araújo F; Aguiar P; Marinho A; Oliveira A; Gomes D
    Acta Med Port; 2014; 27(4):525-9. PubMed ID: 25203965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
    Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
    J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.
    Lévesque S; Auray-Blais C; Gravel E; Boutin M; Dempsey-Nunez L; Jacques PE; Chenier S; Larue S; Rioux MF; Al-Hertani W; Nadeau A; Mathieu J; Maranda B; Désilets V; Waters PJ; Keutzer J; Austin S; Kishnani P
    Orphanet J Rare Dis; 2016 Jan; 11():8. PubMed ID: 26809617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
    Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pregnancy and associated events in women receiving enzyme replacement therapy for late-onset glycogen storage disease type II (Pompe disease).
    Rohman PJ; Scott E; Richfield L; Ramaswami U; Hughes DA
    J Obstet Gynaecol Res; 2016 Oct; 42(10):1263-1271. PubMed ID: 27384519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
    Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
    Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.